Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
145.58
-0.27 (-0.19%)
Dec 26, 2024, 4:00 PM EST - Market closed
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $22.47B in the quarter ending September 29, 2024, with 5.25% growth. This brings the company's revenue in the last twelve months to $87.70B, up 4.77% year-over-year. In the year 2023, Johnson & Johnson had annual revenue of $85.16B with 6.46% growth.
Revenue (ttm)
$87.70B
Revenue Growth
+4.77%
P/S Ratio
4.00
Revenue / Employee
$664,867
Employees
131,900
Market Cap
350.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
| Dec 28, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher | 42.37B |
| Abbott Laboratories | 41.22B |
| Eli Lilly | 40.86B |
JNJ News
- 10 hours ago - US FDA proposes standardized testing to detect asbestos in talc products - Reuters
- 1 day ago - Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025 - Benzinga
- 7 days ago - Johnson & Johnson: Dividend Legend At A Discount - Seeking Alpha
- 8 days ago - Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To Buy - Seeking Alpha
- 8 days ago - Health Rounds: J&J drug helps delay multiple myeloma in high-risk patients - Reuters
- 8 days ago - Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant - GlobeNewsWire
- 10 days ago - US FDA declines to approve injection form of J&J's lung cancer drug - Reuters
- 13 days ago - J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports - Reuters